Anabolics vs. Mitochondrial Peptides: How Each One Works

Two Different Targets

Comparing traditional anabolic agents (AAS) to mitochondrial peptides is like comparing a sledgehammer to a scalpel. Both are tools people use for changing physique and performance, but they operate on completely different principles and for different ends.

The sledgehammer, meaning testosterone and derivatives such as nandrolone, is for building new structures. It's for adding mass. It works through hormonal signaling at the androgen receptor to drive hypertrophy. The scalpel, peptides like MOTS-c and SS-31, is aimed at refinement: making the muscle you already have work better and for longer. It targets the source of cellular energy, and the evidence for it is far thinner.

Confusing the two is a common mistake. Expecting MOTS-c to pack on 20 pounds misreads what it does. Expecting testosterone to fine-tune your mitochondrial function for endurance is missing the point too. This page compares the mechanisms; for what has actually been measured, and in whom, see our comparison of measured outcomes for mitochondrial peptides and steroids.

How Anabolic Steroids Build Muscle

The mechanism has been understood for decades. An exogenous androgen binds to the androgen receptor (AR) inside muscle cells, and this complex then travels to the cell's nucleus to directly influence gene expression.

The result is an upregulation in muscle protein synthesis and increased nitrogen retention. Pathways like the mammalian target of rapamycin (mTOR), the central regulator of cell growth, are also involved, though researchers are still working out how much of the effect runs through mTOR. This is why AAS are the best-documented agents for increasing raw muscle size and strength.

The human data are direct. In a 1996 randomized trial in the New England Journal of Medicine, 43 healthy men got supraphysiologic testosterone or placebo for 10 weeks, with or without weight training. Testosterone increased muscle size and strength even in the men who didn't train, and the testosterone-plus-training group gained about 6 kg of fat-free mass.

This sledgehammer approach comes with systemic consequences. You're fundamentally altering the body's endocrine system. HPTA suppression (shutdown of natural testosterone production) is expected. Managing estrogen and monitoring lipids are part of the deal, along with long-term cardiovascular and prostate risk. In the US, anabolic steroids are Schedule III controlled substances under federal law, and WADA prohibits them at all times (S1).

The Mitochondrial Method: Optimizing the Powerhouse

Mitochondrial peptides don't even knock on the androgen receptor's door, and nothing published suggests they drive growth through mTOR. They operate somewhere else entirely, targeting the tiny organelles inside your cells responsible for generating ATP: your mitochondria. Nearly everything known about how they work comes from animal and cell studies.

MOTS-c: The AMPK Signal

MOTS-c is often called an "exercise-mimetic." It's a peptide that your own mitochondria produce naturally, encoded in mitochondrial DNA and first described in a 2015 Cell Metabolism paper. Giving it exogenously is meant to tell cells they are undergoing strenuous activity even when they're not, an idea based on mouse studies.

Its primary mechanism is activating AMP-activated protein kinase (AMPK). Think of AMPK as the cell's fuel gauge. When energy is low (or the cell thinks it is), AMPK gets switched on. In general, AMPK activation triggers a cascade of events:

• Increased fatty acid oxidation (burning fat for fuel).
• Improved glucose uptake into muscle cells (enhancing insulin sensitivity).
• Signals toward mitochondrial biogenesis (building new mitochondria).

In the 2015 study, MOTS-c treatment in mice improved insulin sensitivity and prevented weight gain on a high-fat diet. So, while anabolics are telling the cell to grow bigger (mTOR), MOTS-c is telling it to become more energy-efficient (AMPK). AMPK tends to dampen mTOR activity, so the two signals partly oppose each other. The claimed effects are on endurance and body composition, not raw size, but they've been shown in mice, not people.

As of October 2026, we found no published study that has given native MOTS-c to people. The nearest data come from an analog, CB4211, tested for four weeks in adults with obesity and fatty liver disease: liver enzymes fell compared with placebo, but liver fat dropped substantially in both groups. WADA's 2026 Prohibited List names MOTS-c under S4.4.1 (AMPK activators), so it's banned at all times for tested athletes.

SS-31 (Elamipretide): The Cardiolipin Binder

If MOTS-c is about building a better power grid, SS-31 (elamipretide) is pitched as the crew that repairs the existing grid. Intense training creates oxidative stress, and the proposed target is a key lipid in the inner mitochondrial membrane called cardiolipin.

Damaged cardiolipin makes the mitochondrial membrane leaky and inefficient. The electron transport chain, where ATP is made, starts to sputter, and energy production drops. Users and vendors link this to poor recovery between workouts and hitting a wall mid-session, but no study has measured that link in healthy people who train.

SS-31 is highly specific. A 2014 review by Hazel Szeto, whose lab developed it, describes how it homes in on the inner mitochondrial membrane and binds directly to cardiolipin, keeping cytochrome c working as an electron carrier and helping preserve the membrane's structure. That review drew mainly on animal studies. SS-31 doesn't build new mitochondria; the proposed effect is on how the existing ones work.

SS-31 is also the only compound on this page with a drug approval. On September 19, 2025, the FDA granted accelerated approval to elamipretide as Forzinity, a prescription medicine for Barth syndrome, a rare inherited mitochondrial disease. The approval rests on knee muscle strength in a 12-patient trial whose primary endpoints (6-minute walk distance and fatigue) weren't met, and the FDA requires a confirmatory trial. A Phase 2 trial in dry macular degeneration (ReCLAIM-2) also missed its primary endpoints. Research-use vials sold online aren't the approved product.

Head-to-Head: Mechanism by Mechanism

If your only goal is to be as big and strong as possible for a powerlifting meet, mitochondrial peptides have no evidence behind them for that, and anabolics are the class with direct human data. That's a statement about evidence, not a recommendation. For the bodybuilder who needs to get through high-volume workouts week after week, or the athlete whose sport depends on repeatable power output, mitochondrial peptides are the ones being marketed, but the support is rodent data and user reports. For how MOTS-c and SS-31 compare with each other, see our side-by-side look at mitochondrial peptides.

The Build-and-Tune Claim

A common argument in forums and vendor content is that the smartest approach is synergistic. The claim runs like this: anabolic agents build the new muscle tissue, a bigger engine, and mitochondrial peptides like MOTS-c and SS-31 improve the metabolic function of that new tissue, tuning the bigger engine to be more efficient and last longer.

Proponents say this avoids building mass that lacks the metabolic machinery to support its performance demands. In this framing, the anabolics provide the stimulus for size, and the mito-peptides provide the capacity to recover from and adapt to that stimulus.

No study has tested it. As of October 2026, we found no trial, in animals or people, that combined AAS with MOTS-c or SS-31 and measured performance or safety. The mechanisms may also pull against each other: AMPK activation tends to dampen mTOR signaling, which androgen-driven growth partly relies on. Exercise engages both pathways at different times, so this may not matter in practice, but nobody has measured it. Combining them also stacks the known risks of steroids on top of the unknowns of unregulated peptide vials.

What We Still Don't Know

• Whether native MOTS-c does anything measurable in people. As of October 2026, there's no published human administration study.
• Whether SS-31's benefit in Barth syndrome holds up in the required confirmatory trial.
• Whether either peptide changes recovery or endurance in healthy trained people, alone or alongside steroids.
• How WADA treats SS-31 now that it's an approved drug. It isn't named on the 2026 list.

Why "which is better" is the wrong question for these two classes is covered in our piece on peptides versus steroids.

Comparison table